Abstract
BackgroundWhile immune-based therapies induce durable remissions in subsets of patients across a wide range of malignancies, efficacy in metastatic castrate-resistant prostate cancer (mCRPC) is limited.1–3 One hypothesis for immunotherapy failure...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have